(NASDAQ: CAI) Caris Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.22%.
Caris Life Sciences's revenue in 2025 is N/A.On average, 9 Wall Street analysts forecast CAI's revenue for 2025 to be $190,897,747,612, with the lowest CAI revenue forecast at $167,232,737,578, and the highest CAI revenue forecast at $202,065,157,576.  On average, 9 Wall Street analysts forecast CAI's revenue for 2026 to be $278,347,201,211, with the lowest CAI revenue forecast at $263,307,335,060, and the highest CAI revenue forecast at $297,253,899,068.  
In 2027, CAI is forecast to generate $345,343,224,272 in revenue, with the lowest revenue forecast at $316,939,587,748 and the highest revenue forecast at $377,965,222,656.